杭州洛澳进出口有限公司

10
Years
基本信息
贸易信息
工商信息

基本信息

企业名称
杭州洛澳进出口有限公司
企业地址
浙江省杭州市拱墅区绿地运河商务中心3幢1701室
年销售额(USD):
不愿意公开
成立年份t:
2005
企业规模(人):
100至149
主要竞争优势
品牌,国际认证/标准,经验丰富的研发人员,发货速度,生产能力,产品线丰富,合同定制(CRO,CMO),接受买家的规格要求,接受小额订单,良好的信誉,优质服务
邮政编码
310021
官网地址
www.royalpharms.com
其他竞争优势
合同定制
专利与版权
商标
企业简介
杭州洛澳进出口有限公司拥有自营进出口权,主要从事原料药、医药中间体、生物化工产品、合同定制以及制药机械等产品的进出口贸易,同时代理其它产品的进出口业务。公司在国内外建立了较完整的采购与营销网络,产品已出口至俄罗斯、伊朗、约旦、埃及、萨摩亚、越南、印度、巴基斯坦、韩国等多个国家。凭借丰富的国际贸易经验、专业化的队伍和良好的企业信誉,我们愿意与国内外客户、友人建立长期稳定的商业合作伙伴关系,共谋发展。

贸易信息

业务类型
制造商,出口商,贸易公司,服务商
主要销售市场
北美洲,中/南美洲,西欧,东欧,大洋洲,亚洲,中东,非洲
主营产品类别
原料药,生物制品,药用辅料,原料药设备,医药包装机械,制药用水设备,实验室仪器及装备
交货方式
FOB,CFR,CIF,EXW
支付方式
信用证,提单,电汇,付款交单
产品外销比重
100%%

工商信息

该企业工商信息校验数据由
提供
企业名称
杭州洛澳进出口有限公司
经营状态
存续
注册资本
100万人民币
统一社会信用代码
913301035995584804
核准时间
2022-04-01
人员规模
小于50人
注册地址
浙江省杭州市拱墅区绿地运河商务中心3幢1701室
法定代表人
曹慧慧
成立日期
2012-07-16
工商注册号
330103000159369
营业期限
2012-07-16至2032-07-15
企业类型
有限责任公司(自然人投资或控股)
登记机关
杭州市拱墅区市场监督管理局
经营范围
一般项目:货物进出口;技术进出口;进出口代理;机械设备销售;制浆和造纸专用设备销售;化工产品销售(不含许可类化工产品);专用化学产品销售(不含危险化学品);建筑材料销售;包装材料及制品销售;日用百货销售;服装服饰批发;五金产品批发;电子产品销售;纸制品销售;家具销售;特种劳动防护用品销售;互联网销售(除销售需要许可的商品);信息咨询服务(不含许可类信息咨询服务)(除依法须经批准的项目外,凭营业执照依法自主开展经营活动)。许可项目:药品进出口(依法须经批准的项目,经相关部门批准后方可开展经营活动,具体经营项目以审批结果为准)。

公司证书

商标
royal 商标
QIP-ASI223162
IS9001-2015

新闻资讯

Aleniglipron API: A Breakt hrough for Weight Loss!
Aleniglipron (CAS: 2685823-26-9) is an oral GLP-1 small molecule, just like Orforglipron, designed as a weight-loss API.Recently, Structure Therapeutics announced the topline results of the Phase II ACCESS II trial for once-daily oral Aleniglipron, creating a global buzz in the weight-loss drug field.Aleniglipron shows no plateau effect and significantly improved tolerability, earning multiple institutions’ “best-in-class” rating — positioning it as a strong challenger to Eli Lilly’s Orforglipron.
2026-10-12
查看详情
Royal at CPHI 2026 SHENZHOU
Royal at CPHI 2026 SHENZHOU
2026-10-12
查看详情
Royal Pharm to Exhibit at CPHI China 2026 in Shanghai
To expand our business opportunities, strengthen industry connections, and communicate face-to-face with more customers, Royal Pharm will participate in CPHI China 2026, which will be held in Shanghai this June.Through this exhibition, we hope to establish stronger partnerships with customers and industry professionals worldwide, bringing Royal Pharm’s high-quality products to broader international markets and delivering reliable solutions to customers around the globe.Exhibition Date: June 16–18, 2026Venue: Shanghai New International Expo CentreBooth Number: W7B02We sincerely look forward to meeting you at the exhibition and exploring future cooperation together!
2026-05-29
查看详情
Royal Showcases Star Product RLD at IPhEB Russia 2026
From April 7 to 9, 2026, Royal proudly participated in the IPhEB Russia pharmaceutical exhibition, a leading platform bringing together top global companies and cutting-edge technologies in the industry.During the event, Royal showcased its advanced capabilities in drug development and manufacturing and officially launched its star product — the Reference Listed Drug (RLD). As a reference listed drug, RLD is an innovative medicine approved through rigorous clinical trials and serves as the standard for bioequivalence studies and quality comparisons for generic drugs. By using RLD as a benchmark, generic drugs can ensure comparable efficacy and safety, providing patients with reliable treatment options. RLD attracted significant attention from industry professionals at the exhibition, who recognized its high quality and regulatory compliance. This event further strengthened Royal’s presence in the international pharmaceutical market and highlighted the company’s ongoing commitment to innovation and high-quality drug development. Royal will continue to provide safe and effective pharmaceutical solutions for the global healthcare industry.
2026-05-26
查看详情
2006-2026 上海博华国际展览有限公司版权所有(保留一切权利)
沪ICP备05034851号-57